Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

Vertex shares fell in after-hours trading, as investors considered a stock trading near its all-time high with a longer wait ...

Vertex, Inc. (VERX) kicks off 2025 strong with 12.9% revenue growth, strategic AI investments, and e-invoicing innovations.

Vertex also picked up a positive Committee for Medicinal Products for Human Use (CHMP) opinion for Alyftrek. As a result, it's looking for European Commission approval for the drug in the second half ...

A polynomial is a type of algebraic equation that involves variables raised to a non-negative power — for example, x² + 5x + ...

Turbulence is a notoriously difficult phenomenon to study. Mathematicians are now starting to untangle it at its smallest ...

Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.15 per share a year ago. These figures are ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Vertex (VERX) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important ...